David A. Siegel Surface Oncology, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.57 - $0.88 $5,073 - $7,832	-8,900 Reduced 25.57%	25,900 $22,000
Q4 2022 Feb 14, 2023	SELL	$0.62 - $1.21 $6,014 - $11,737	-9,700 Reduced 21.8%	34,800 $28,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $12,495 - $24,990	11,900 Added 36.5%	44,500 $46,000
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $3,692 - $8,190	2,600 Added 8.67%	32,600 $53,000
Q1 2022 May 16, 2022	BUY	$2.65 - $5.08 $13,780 - $26,416	5,200 Added 20.97%	30,000 $88,000
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $117,304 - $195,920	24,800 New	24,800 $119,000
Q2 2021 Aug 16, 2021	SELL	$6.45 - $9.09 $927,510 - $1.31 Million	-143,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$7.25 - $13.82 $414,700 - $790,504	-57,200 Reduced 28.46%	143,800 $1.12 Million
Q4 2020 Feb 16, 2021	SELL	$6.87 - $10.48 $645,780 - $985,120	-94,000 Reduced 31.86%	201,000 $1.86 Million
Q3 2020 Nov 16, 2020	BUY	$5.06 - $7.23 $828,321 - $1.18 Million	163,700 Added 124.68%	295,000 $2.04 Million
Q2 2020 Aug 14, 2020	BUY	$1.57 - $6.56 $206,141 - $861,328	131,300 New	131,300 $861,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.